REFERENCES
- Kurth KH, Bouffioux C, Sylvester R, van der Meij den APM, Oosterlinck W, Brausi M and members of the EORTC Genitourinary Group. Treatment of superficial bladder tumors: achievements and needs. Eur Urol 2000; 37 (Suppl. 3): 1–9.
- Prout GR Jr, Barton BA, Griffin PP, Friedell GH. Treated history of noninvasive grade 1 transitional cell carcino-ma. J Urol 1992; 148: 1413–19.
- Schwaibold H, Pichlmeier U, Klingenberger HJ, Huland H. Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcino-ma. Eur Urol 1997; 31: 153–9.
- Kurth KH, Schroder FH, Tunn U, Ay R, Pavone-Macaluso M, Debruyne F, et al. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone. J Urol 1984; 132: 258–62.
- Lamm DL, Blurnenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacil-lus Calmette-Guirin for transitional-cell carcinoma of the bladder. N Engl J Med 1991; 325: 1205–9.
- Lundholm C, Norlen BJ, Ekman P, Jahnson S, Lagerkvist M, Lindeborg T, et al. A randomized prospective study comparing long-term intravesical instillations of mito-mycin C and bacillus Calmette-Guirin in patients with superficial bladder carcinoma. J Urol 1996; 156: 372–6.
- Lamm DL, Steg A, Boccon-Gibod L, Morales A, Hanna MG Jr, Pagano F, et al. Complications of bacillus Calmette-Guerin immunotherapy: review of 2602 pa-tients and comparison of chemotherapy complications. Prog Chin Biol Res 1989; 310: 335–55.
- Thanhauser A, Bohle A, Schneider B, Reiling N, Mattem T, Ernst M, et al. The induction of bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 1995; 40: 103–8.
- Prescott S, James K, Hargreave TB, Chisholm GD, Smyth if. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 1990; 144: 1248–51.
- Stavropoulos NE, Ioachim E, Pappa L, Hastatzeris K, Agnantis NJ. Antiproliferative activity of interferon gamma in superficial bladder cancer. Anticancer Res 1999; 19: 4529–33.
- Stavropoulos NE, Ioachim E, Pavlidis N, Pappa L, Kalomiris P, Agnantis NJ. Local immune response after intravesical interferon gamma in superficial bladder cancer. Br J Urol 1998; 81: 875–9.
- Geboers ADH, Van Bergen TNLM, Oosterlinck N. Gamma-interferon in the therapeutic and prophylactic management of superficial bladder cancer. J Urol 1987; 137 (part 2): 276 (abstract 691).
- Zlotta AR, Schulman CC. Biological response modifiers for the treatment of superficial bladder tumors. Eur Urol 2000; 37 (suppl 3): 10–15.
- Aulitzky WE, Aulitzky W, Gastl G, Lanske B, Reitter J, Frick J, et al. Acute effects of single doses of recombinant interferon gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer. J Interferon Res 1989; 9: 425–33.
- Giannakopoulos S, Gekas A, Alivizatos G, Sofras F, Becopoulos T, Dimopoulos C. Efficacy of escalating doses of intravesical interferon a-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma. Br J Urol 1998; 82: 829–34.
- Portallo J, Martin B, Hernandez R, Correas M, Gutierrez J, Del Valle J, et al. Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology 1997; 49: 187–90.
- Kurth KH, Denis L, Bouffioux C, Sylvester R, Debruyne FM, Pavone-Macaluso M, et al. Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer 1995; 31A: 1840–6.
- Kalble T, Beer M, Mendoza E, Ikinger U, Link M, Reichert HE, et al. BCG versus interferon A for prevention of recurrence of superficial bladder cancer: a prospective randomized study. Urologe A 1994; 33: 133–7.
- Lamm DL, Riggs DR, Traynelis CL, Nseyo UO. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of super-ficial transitional cell carcinoma of the bladder. J Urol 1995; 153: 1444–50.
- Belldegrun AS, Franklin JR, O'Donnel MA, Gomella LG, Klein E, Neri R, et al. Superficial bladder cancer: the role of interferon-a. J Urol 1998; 159: 1793–801.
- O'Donnell MA, Chen X, Luo Y, DeWolf WC. Experi-mental and clinical evidence of enhancement of BCG efficacy by adding interferon-alpha. J Urol (part 2) 1997; 157: 383 (abstract 1502).